Ligand Pharmaceuticals (LGND) News Today $106.40 +0.78 (+0.74%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Bank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Bank of New York Mellon Corp lowered its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 3.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,992 sharesMarch 13 at 3:06 AM | marketbeat.comCallan Family Office LLC Takes Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Callan Family Office LLC acquired a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,438 shares of the biotechnoMarch 12 at 3:52 AM | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Stock Rating Lowered by StockNews.comMarch 12 at 1:19 AM | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Downgraded by StockNews.com to "Sell"StockNews.com lowered shares of Ligand Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday.March 11 at 11:03 PM | marketbeat.comBarclays Keeps Their Buy Rating on Ligand Pharma (LGND)March 10, 2025 | markets.businessinsider.comEssex Investment Management Co. LLC Sells 3,901 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Essex Investment Management Co. LLC lowered its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 5.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,247 shares of the biotechnology company'sMarch 10, 2025 | marketbeat.comLisanti Capital Growth LLC Has $4.18 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Lisanti Capital Growth LLC boosted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 57.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,010 shares of the biotechnology company's sMarch 8, 2025 | marketbeat.comOctavio Espinoza Sells 5,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) CFO Octavio Espinoza sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $115.03, for a total transaction of $575,150.00. Following the completion of the transaction, the chief financial officer now directly owns 18,879 shares in the company, valued at approximately $2,171,651.37. The trade was a 20.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 7, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Sells $575,150.00 in StockMarch 7, 2025 | insidertrades.comDana Investment Advisors Inc. Sells 4,373 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Dana Investment Advisors Inc. lessened its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 5.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 76,229 shares of the biotechnolMarch 6, 2025 | marketbeat.comCookson Peirce & Co. Inc. Purchases 2,755 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Cookson Peirce & Co. Inc. grew its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 56.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,650 shares of the biotechnoMarch 6, 2025 | marketbeat.comFisher Asset Management LLC Increases Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Fisher Asset Management LLC increased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 68.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 100,638 shares of the biotecMarch 5, 2025 | marketbeat.comBrokerages Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PT at $147.00March 5, 2025 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Trading Down 8.8% - Here's WhyLigand Pharmaceuticals (NASDAQ:LGND) Trading Down 8.8% - What's Next?March 4, 2025 | marketbeat.comLGND: First Steps into Cell & Gene TherapyMarch 3, 2025 | msn.comLigand Pharma (LGND) Receives a Buy from RBC CapitalMarch 3, 2025 | markets.businessinsider.comLigand to Participate in March Investor ConferencesMarch 3, 2025 | globenewswire.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of "Buy" by BrokeragesLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has been given an average rating of "Buy" by the six analysts that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokMarch 2, 2025 | marketbeat.comPrincipal Financial Group Inc. Purchases 6,382 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Principal Financial Group Inc. raised its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 6.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 99,590 shares of the biotechnoMarch 1, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3% - Should You Buy?Ligand Pharmaceuticals (NASDAQ:LGND) Shares Up 7.3% - Here's What HappenedFebruary 28, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Releases Quarterly Earnings ResultsLigand Pharmaceuticals (NASDAQ:LGND - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($1.64) earnings per share for the quarter, missing analysts' consensus estimates of $1.37 by ($3.01). Ligand Pharmaceuticals had a return on equity of 4.95% and a net margin of 29.68%.February 28, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comOppenheimer Sticks to Their Buy Rating for Ligand Pharma (LGND)February 28, 2025 | markets.businessinsider.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | insidermonkey.comLigand Pharmaceuticals (NASDAQ:LGND) Issues FY 2025 Earnings GuidanceLigand Pharmaceuticals (NASDAQ:LGND) updated its FY 2025 earnings guidance. The company provided EPS guidance of 6.000-6.250 for the period, compared to the consensus estimate of 6.140. The company also issued revenue guidance of $180.0 millionillion-$200.0 millionillion, compared to the consensus estimate of $188.8 millionillion.February 28, 2025 | marketbeat.comLigand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...February 28, 2025 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Reports Strong 2024 Financial Results and Reaffirms 2025 GuidanceFebruary 27, 2025 | gurufocus.comLigand Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | globenewswire.comLigand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need To Know Ahead Of EarningsFebruary 26, 2025 | gurufocus.comNew York State Common Retirement Fund Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)New York State Common Retirement Fund lifted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 7.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,418 shares of the biotechnologFebruary 26, 2025 | marketbeat.comLigand leads $75M royalty financing in Castle CreekFebruary 25, 2025 | markets.businessinsider.comLigand Leads $75 Million Royalty Financing in Castle Creek BiosciencesFebruary 25, 2025 | globenewswire.comState of New Jersey Common Pension Fund D Invests $2.01 Million in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)State of New Jersey Common Pension Fund D acquired a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 18,776 sharesFebruary 24, 2025 | marketbeat.comLigand Pharmaceuticals Inc.February 20, 2025 | jp.wsj.comAllspring Global Investments Holdings LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Allspring Global Investments Holdings LLC trimmed its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 13.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 100,062 shares of theFebruary 19, 2025 | marketbeat.comRice Hall James & Associates LLC Cuts Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Rice Hall James & Associates LLC decreased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 2.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investorFebruary 18, 2025 | marketbeat.comAcuitas Investments LLC Sells 12,749 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Acuitas Investments LLC cut its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 31.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,512 shares of the biotechnology company's stock afFebruary 18, 2025 | marketbeat.comLigand Pharmaceuticals (LGND) to Release Quarterly Earnings on TuesdayLigand Pharmaceuticals (NASDAQ:LGND) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666040)February 18, 2025 | marketbeat.comVillere ST Denis J & Co. LLC Sells 187,814 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Villere ST Denis J & Co. LLC reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 39.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 287,044 shFebruary 16, 2025 | marketbeat.comCongress Asset Management Co. Buys 17,444 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Congress Asset Management Co. increased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 621,482 shares of the biotechnology company's stock after puFebruary 16, 2025 | marketbeat.comLigand Pharmaceuticals Inc (LGND) Announces Upcoming Financial Results Release and Conference CallFebruary 13, 2025 | gurufocus.comStephens Investment Management Group LLC Sells 5,914 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Stephens Investment Management Group LLC lessened its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 1.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 612,782 shares of the biotechnology compaFebruary 9, 2025 | marketbeat.comabrdn plc Sells 72,509 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)abrdn plc trimmed its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 29.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 176,760 shares of the biotechnology company's stockFebruary 7, 2025 | marketbeat.comLigand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 7, 2025 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Buy" from BrokeragesLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has been given an average rating of "Buy" by the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objFebruary 5, 2025 | marketbeat.comLooking Back On Ligand PharmaceuticalsFebruary 3, 2025 | seekingalpha.comChicago Capital LLC Has $59.10 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Chicago Capital LLC boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 551,588 shares of the bioteFebruary 3, 2025 | marketbeat.comHantz Financial Services Inc. Takes $839,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Hantz Financial Services Inc. acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 7,827 shares of the biotechnology cFebruary 1, 2025 | marketbeat.comCourt Place Advisors LLC Decreases Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Court Place Advisors LLC lessened its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 57.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,783 shares of the biotechnologyJanuary 28, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Stock Crosses Above 200 Day Moving Average - Here's WhyLigand Pharmaceuticals (NASDAQ:LGND) Shares Cross Above 200 Day Moving Average - Time to Sell?January 25, 2025 | marketbeat.com Remove Ads Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Media Mentions By Week LGND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGND News Sentiment▼1.070.72▲Average Medical News Sentiment LGND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGND Articles This Week▼95▲LGND Articles Average Week Remove Ads Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EXAS News Today RGEN News Today HALO News Today MDGL News Today ALKS News Today IONS News Today FOLD News Today DVAX News Today BCRX News Today MNKD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGND) was last updated on 3/14/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
